Azurin p28 peptide (TFA)

OC(C=C1)=CC=C1C[C@H](NC([C@H](CC(O)=O)NC([C@H](CCCCN)NC([C@H](CC(O)=O)NC([C@H](CC(C)C)NC(CNC([C@H](CO)NC([C@H](C)NC([C@H](CCSC)NC(CNC([C@H](CC(O)=O)NC([C@H]([C@H](O)C)NC([C@H](C(C)C)NC([C@H](C(C)C)NC(CNC([C@H](CCC(N)=O)NC([C@H](CCSC)NC([C@H](CC(O)=O)NC([C@H](C)NC([C@H](C)NC([C@H]([C@H](O)C)NC([C@H](CO)NC([C@@H](N)CC(C)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N2[C@@H](CCC2)C(N[C@@H](CC(O)=O)C(N[C@H](C(O)=O)CC(O)=O)=O)=O)=O)=O)=O.O=C(O)C(F)(F)F.[x]

[1]Mehta RR, et al. A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2, FAK and Akt. Angiogenesis. 2011 Sep;14 (3) :355-69.|[2]Jia L, et al. Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination. Cancer Chemother Pharmacol. 2011 Aug;68 (2) :513-24.|[3]Yamada T, et al. A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells. Mol Cancer Ther. 2009 Oct;8 (10) :2947-58.